Mylan boosts Euro portfolio with $756M rights deal for Aspen’s injectable thrombosis meds
Mylan’s planned megamerger with Pfizer’s Upjohn generics unit has had a rocky road to approval, with the novel coronavirus pandemic snagging regulatory review. Despite the delay, Mylan isn’t twiddling its thumbs: The generics giant is now bolting on a major addition to its EU portfolio as it awaits its merger deadline. Mylan will shell out… Read More »
